Wojciech Morzycki

Halifax, NS, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.

Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.

Journal: PloS one

Published: October 29, 2020

Molecular profiling of non-small cell lung cancer.

Molecular profiling of non-small cell lung cancer.

Journal: PloS one

Published: January 16, 2020

Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.

Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.

Journal: Current oncology (Toronto, Ont.)

Published: September 25, 2019

Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Journal: Current oncology (Toronto, Ont.)

Published: November 23, 2018

Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Journal: Current oncology (Toronto, Ont.)

Published: June 23, 2016

Prevention of alopecia in medical and interventional chemotherapy patients.

Prevention of alopecia in medical and interventional chemotherapy patients.

Journal: Journal of cutaneous medicine and surgery

Published: March 17, 2015

A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada.

A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada.

Journal: Current oncology (Toronto, Ont.)

Published: April 20, 2012

Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.

Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: October 19, 2011

Showing 1-8 of 8

Last Updated: 09/26/2026